Samuel Salot

Samuel Salot has a diverse work experience in the biotechnology industry. Samuel began their career at Innate Pharma in 2002, working as a Project Manager for external collaborations and later as a Project Manager for Cell Therapy. In these roles, they were responsible for coordinating and implementing various projects related to gamma delta T cell therapy, including scale-up, technical transfer, and clinical trials.

In 2009, Salot joined Platine Pharma Services as Chief Operating Officer, where they provided leadership and vision to ensure operational efficiency and financial strength. Samuel was responsible for various aspects of the organization, including operational activities, human resources, financial control, business development, and service provision.

After leaving Platine Pharma Services in 2013, Salot founded CYNBIOSE RESPIRATORY, a company focused on respiratory biotechnology, where they served as Co-founder and General Manager. Samuel contributed to the company's growth and development until May 2020.

From 2015 to 2018, Salot worked at OGD2 Pharma as VP Alliance Management. In this role, they identified and established external collaborations and strategic alliances, focusing on preclinical R&D projects in monoclonal antibody development, antibody-drug conjugates, CAR-T and CAR-NK development, and immunocytokines.

Most recently, Salot joined EG 427 as the Chief Operating Officer in February 2020. EG 427 is a French biotechnology company specializing in gene therapy. As COO, they are responsible for operations and development, including contractor selection and ensuring the delivery of preclinical development packages related to safety, efficacy, and mechanism of action.

Samuel Salot earned a Master's degree in life sciences from École Pratique des Hautes Études in 2006. Later, from 2010 to 2012, they attended emlyon business school where they obtained a Master of Business Administration (M.B.A.) degree.